Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 12/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14327086 | 0.87 | RIPK1 (0.36) | RETKDRRIPK1 | |
| SCHEMBL14312485 | 0.84 | ACVRL1 (0.49) | ACVRL1METRIPK1SRC | |
| SCHEMBL14312813 | 0.83 | ACVRL1 (0.43) | ACVRL1METCFTRRETKDR | |
| SCHEMBL14312898 | 0.79 | ACVRL1 (0.52) | ACVRL1METRIPK1 | |
| SCHEMBL14531789 | 0.78 | CFTR (0.34) | ACVRL1CFTRRIPK1 | |
| SCHEMBL14327129 | 0.77 | EGFR (0.32) | — | |
| SCHEMBL14312757 | 0.77 | ACVRL1 (0.61) | ACVRL1METRIPK1 | |
| SCHEMBL14327088 | 0.77 | RIPK1 (0.34) | ACVRL1RIPK1 | |
| SCHEMBL14313240 | 0.77 | TYRO3 (0.47) | ACVRL1 | |
| SCHEMBL5136879 | 0.76 | ACVRL1 (0.61) | ACVRL1METRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |